Carol and Kenneth Weg Endow Chair in Human Genetics for Fox Chase Cancer Center's Research Institute for Cancer Prevention
PHILADELPHIA (September 28, 1998) -- Carol and Kenneth Weg of Princeton, N.J., have made a $1.5 million gift to Fox Chase Cancer Center as part of the Center's ongoing $38 million campaign for the Research Institute for Cancer Prevention, the first comprehensive cancer prevention research initiative in the country. The gift will endow the Carol and Kenneth Weg Chair in Human Genetics.
Kenneth E. Weg is president of Bristol-Myers Squibb Company's Worldwide Medicines Group, based in Princeton. He also serves as executive vice president of the pharmaceutical firm and as a member of its board of directors.
"Fox Chase is one of the country's leading comprehensive cancer centers and reflects the innovative advances that are under way throughout the health-care community," said Weg. "Both laboratory and clinical research are vital not only in treating cancer patients more effectively but in learning to prevent many cases of cancer in people with special risks."
Weg was elected to the Fox Chase board of directors in February 1998. In announcing the endowment of the Weg Chair in Human Genetics at a prevention-campaign breakfast for Center staff, he noted that the Fox Chase maintains a high standard of excellence in all areas.
"As a center of excellence, Fox Chase staff can be proud that its talents encompass both research and all aspects of the treatment and care of cancer patients," said Weg. "One of the things that really stands out at Fox Chase is the personal attention and sense of caring that the staff gives to every patient and family member.
"My hope is that the new Research Institute for Cancer Prevention will extend the same kind of very special care in helping people prevent cancer."
Weg has more than 30 years of experience in the health-care industry. He joined Bristol-Myers Squibb in 1969 and has played a key role in its management for over a decade.
Weg is a trustee of both the Princeton Medical Center and the Foundation for New Jersey Public Broadcasting.
Fox Chase Cancer Center is one of 34 National Cancer Institute-designated comprehensive cancer centers in the nation. The Center's activities include basic and clinical research, prevention, detection and treatment of cancer and community outreach programs.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy Moore at 215-728-2700.